Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1515/cclm-2021-0126 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Neonatal cost savings in hypertensive disorders of pregnancy: Economic evaluation of the sFlt-1/PlGF test with real world implementation of biomarkers.
Pregnancy Hypertens
January 2025
Division of Maternal Fetal Medicine, Department of Obstetrics & Gynecology, University of Chicago Medical Center, Chicago, IL, USA. Electronic address:
Background: Preeclampsia is a key cause of prematurity in the U.S. and incurs significant healthcare costs.
View Article and Find Full Text PDFSoluble Fms-like tyrosine kinase-1 polymorphisms associated with severe-spectrum hypertensive disorders of pregnancy.
Arch Gynecol Obstet
January 2025
Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, 90089, USA.
Background: sFLT-1 has been implicated in the pathogenesis of HDP. We aimed to examine the role of maternal and fetal polymorphisms in risk of HDP and severe-spectrum disease.
Methods: Cases of HDP (143) and controls (169) from mother-baby dyads were recruited at the Los Angeles County Women's and Children's Hospital (WCH).
Placental biomarkers in second trimester maternal serum are associated with postpartum hemorrhage: a secondary analysis of the NuMoM2b dataset.
medRxiv
January 2025
University of Arizona, College of Nursing, Division of Nursing and Health Sciences, Tucson, Arizona.
Postpartum hemorrhage (PPH) is the leading cause of maternal mortality worldwide, which is often attributed to retained placenta (RP) after delivery. There are no biomarkers currently used to predict a risk of developing RP/PPH prior to labor. The objective of this study was to determine relationships between placental biomarkers measured in the first and second trimesters and proxy measures of postpartum blood loss relative to preeclampsia status in the Nulliparous Pregnancy Outcomes Study: Monitoring Mothers-to-Be (nuMoM2b) dataset.
View Article and Find Full Text PDFExtracellular matrix components in preeclampsia.
Clin Chim Acta
January 2025
Biochemistry Department, Centro Universitário Faculdade de Medicina ABC (FMABC), Santo André, São Paulo, Brazil.
Preeclampsia (PE) is a gestational complication affecting 5% to 10% of all pregnancies. PE is characterized by hypertension and endothelial dysfunction, whose etiology involves, among other factors, alterations in the extracellular matrix (ECM) that can compromise vascular remodeling and trophoblast invasion, ie, processes essential for placental development. Endothelial dysfunction is caused by release of antiangiogenic factors, mainly a soluble fms-like tyrosine kinase-1 (sFlt-1), which antagonizes two endothelial angiogenic factors, the vascular endothelial growth factor (VEGF) and placental growth factor (PLGF).
View Article and Find Full Text PDFAngiogenic factors versus fetomaternal Doppler for fetal growth restriction at term: an open-label, randomized controlled trial.
Nat Med
January 2025
Departament de Pediatria, Obstetrícia i Ginecologia i de Medicina Preventiva i Salut Pública, Universitat Autònoma de Barcelona, Bellaterra, Spain.
Small fetuses, with estimated fetal weight (EFW) below the tenth percentile, are classified as fetal growth restriction (FGR) or small for gestational age (SGA) based on prenatal ultrasound. FGR fetuses have a greater risk of stillbirth and perinatal complications and may benefit from serial ultrasound scans to guide early delivery. Abnormal serum angiogenic factors, such as the soluble fms-like tyrosine kinase-1 (sFlt-1):placental growth factor (PlGF) ratio, have shown potential to more accurately distinguish FGR from SGA, with fewer false positives.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!